CD19-BCMA CAR-T Cell Therapy for Lupus Treatment Refractory Patients
- Here's a breakdown of the provided reference list entries, formatted for clarity:
- Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy.
- * DOI: 10.1158/1078-0432.CCR-21-2031 * PubMed: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36768199 * PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401500 * Google Scholar: http://scholar.google.com/scholar_lookup?&title=Risk%20factors%20associated%20with%20durable%20progression-free%20survival%20in%20patients%20with%20relapsed%20or%20refractory%20multiple%20myeloma%20treated%20with%20anti-BCMA%20CAR%20T-cell%20therapy&journal=Clin.%20Cancer%20Res.&doi=10.1158%2F1078-0432.CCR-21-2031&volume=27&pages=6384-6392&publication_year=2021&author=Zhang%2CM
Here’s a breakdown of the provided reference list entries, formatted for clarity:
23. Zhang, M. et al. Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy. clin. Cancer res. 27, 6384-6392 (2021).
* DOI: 10.1158/1078-0432.CCR-21-2031
* PubMed: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36768199
* PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401500
24. Song, F. et al. Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL. J. Immunother. Cancer 11, e005701 (2023).
* DOI: 10.1136/jitc-2022-005701
* Article: https://doi.org/10.1136%2Fjitc-2022-005701
* PubMed Central: [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944646](http